NF2105

(1) To evaluate the effect of a high-fat diet on the pharmacokinetic response of a single oral administration of NF2105 capsules to healthy subjects; (2) To evaluate the effect of NF2105 capsules (before or after meals) and nilotinib (400 mg) capsules on the QT/QTc interval after fasting administration to healthy Chinese subjects; (3) To preliminarily evaluate the relative bioavailability of NF2105 capsules and nilotinib capsules after a single oral administration to healthy subjects on an empty stomach; (4) To evaluate the PK characteristics and PK/PD (QT/QTc interval) of a single oral administration of NF2105 capsules (fasting or after meals) and nilotinib capsules (fasting) to healthy subjects; (5) To evaluate the safety of oral administration of NF2105 capsules or nilotinib capsules to healthy subjects.